Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of JYP0015 monotherapy in RAS-mutant advanced solid tumors
CTR20250767Phase 2Active
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Apr 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ERAS-0015 in Nonhematologic neoplasms, sponsored by Guangzhou JOYO Pharma. Started Apr 2025; status: active.
02
Drugs
ERAS-0015
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20250767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250767.